A multi-site, double-blind, placebo-controlled trial of memantine vs. placebo in children with autism targeting memory and motor planning

ID Number 11-0410

Principal Investigator(s)
David Grodberg

Department(s) or Division(s)


This study examines the role of memantine (brand name: Namenda) on improving memory, language, and motor abilities in children with Autism Spectrum Disorders (ASDs). Funded by Autism Speaks’ Clinical Trial Network (CTN), this study is designed to further investigate promising preliminary data on the potential role of memantine in improving these important skill areas in children with ASD. Participants will be randomized to receive 24 weeks (6 months) of treatment with memantine or placebo (sugar pill). Participants who did not show improvements and were randomized to placebo are eligible to receive the drug under the clinical care of a study psychiatrist for a 12-week period. This research is conducted by the Seaver Autism Center.

Contact Information
Hillary Rieger
(212) 241-2826

Recruiting Patients: Yes